Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.
about
CCR5 antagonism in HIV infection: current concepts and future opportunitiesIDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platformReliable genotypic tropism tests for the major HIV-1 subtypesLimited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapyA genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patientsA diagnostic HIV-1 tropism system based on sequence relatedness.Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.Covariance of charged amino acids at positions 322 and 440 of HIV-1 Env contributes to coreceptor specificity of subtype B viruses, and can be used to improve the performance of V3 sequence-based coreceptor usage prediction algorithms.Effect of lysine to arginine mutagenesis in the V3 loop of HIV-1 gp120 on viral entry efficiency and neutralization.The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa.Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithmPast, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.Possible involvement of distinct phylogenetic clusters of HIV-1 variants in the discrepancies between coreceptor tropism predictions based on viral RNA and proviral DNA.HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of Cenicriviroc Study 202, a randomized phase II trial in treatment-naive subjects.Dual-mixed HIV-1 coreceptor tropism and HIV-associated neurocognitive deficits.Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findingsThe XTrack system: application and advantage.Drug-diagnostic co-development: challenges and issues.Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression.Assessment of Maraviroc Exposure-Response Relationship at 48 Weeks in Treatment-Experienced HIV-1-Infected Patients in the MOTIVATE Studies.Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.Five Antiretroviral Drug Class-Resistant HIV-1 in a Treatment-Naïve Patient Successfully Suppressed with Optimized Antiretroviral Drug Selection.HIV Co-receptor usage in HIV-related non-hodgkin's lymphoma.Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing
P2860
Q26865457-2631B35D-263D-440F-A6FA-9FE43E522F43Q28543211-BF986315-5E23-4023-8079-7A7200E30E7CQ30372085-16E64D5F-5816-4F87-B2E3-5400B88A7C2BQ33721466-9EC9236F-EB4D-4CF9-989A-8DFECEEF8272Q34431102-F774921E-1D4D-4AB3-BE5C-1794CD7963AFQ34983107-252819AD-E904-4A25-BD92-67A4183050C8Q35270923-F1565B38-CB29-458A-8B3F-53A346FA2963Q35330357-B80225F7-1BEB-4F6D-B407-2CA2E3E3C9B4Q35580330-785AD438-E682-4AD8-9994-93DCE00CC62EQ35818419-D3FCF9F5-672A-4138-95C5-EA3C36E13099Q36298503-82F90AF1-7AE4-4C7B-9769-EC752DF84030Q36690585-1D9132E6-79CB-494B-8A05-01989CD70E21Q36779718-0658C40F-EBF4-4A25-B4AE-E20004D9D4BDQ37335890-F67D6C4A-F082-4992-A5C0-FAE5D747F62CQ37405921-753D430B-9418-4774-A6D5-19FED624EF85Q37525642-DA1950AB-835B-4154-9D9D-3C05194B42B9Q37547823-E69F48CF-F6B3-4629-84AC-5A4C3C2D525FQ37577734-5F2E2419-4DA3-4D60-A162-6E339E4C9663Q37613476-C1D6D6A4-3E93-44ED-8B21-C3619461BA89Q37979701-21FCF38D-44C5-4862-9FE6-A26C3C9E506BQ38664437-B39596EA-465C-4A2B-83E0-305EC185D5D3Q38794079-4930A449-6224-4585-B85B-7C250D85EAE4Q39098454-5062C757-2619-48F3-99CB-0A38FB5EBF7CQ39536633-4103FC6B-8B79-474B-BA1F-4A0C8AFD4B6BQ41101883-B1F02FF9-4A8C-47B3-B211-EB14D3589888Q42138493-4F81B705-93F8-4314-B257-E3DEB871B781Q56792140-C8808C22-FDC7-4EAC-BDA1-72083F458D5C
P2860
Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Reanalysis of coreceptor tropi ...... say with enhanced sensitivity.
@ast
Reanalysis of coreceptor tropi ...... say with enhanced sensitivity.
@en
type
label
Reanalysis of coreceptor tropi ...... say with enhanced sensitivity.
@ast
Reanalysis of coreceptor tropi ...... say with enhanced sensitivity.
@en
prefLabel
Reanalysis of coreceptor tropi ...... say with enhanced sensitivity.
@ast
Reanalysis of coreceptor tropi ...... say with enhanced sensitivity.
@en
P2093
P2860
P356
P1476
Reanalysis of coreceptor tropi ...... say with enhanced sensitivity.
@en
P2093
Doug Chapman
Ellen S Chan
Eoin Coakley
Gail Skowron
Jacqueline D Reeves
Jayyant Heera
John Spritzler
Mathew Bidwell Goetz
Robert Leduc
Roy M Gulick
P2860
P304
P356
10.1093/CID/CIR072
P407
P577
2011-04-01T00:00:00Z